DK2366031T3 - Fremgangsmåder til sekventering i prænatale diagnoser - Google Patents
Fremgangsmåder til sekventering i prænatale diagnoser Download PDFInfo
- Publication number
- DK2366031T3 DK2366031T3 DK10830938.6T DK10830938T DK2366031T3 DK 2366031 T3 DK2366031 T3 DK 2366031T3 DK 10830938 T DK10830938 T DK 10830938T DK 2366031 T3 DK2366031 T3 DK 2366031T3
- Authority
- DK
- Denmark
- Prior art keywords
- chromosome
- sequencing
- sequence
- fetal
- sample
- Prior art date
Links
- 238000012163 sequencing technique Methods 0.000 title claims description 372
- 238000000034 method Methods 0.000 title claims description 250
- 210000000349 chromosome Anatomy 0.000 claims description 794
- 150000007523 nucleic acids Chemical class 0.000 claims description 393
- 102000039446 nucleic acids Human genes 0.000 claims description 356
- 108020004707 nucleic acids Proteins 0.000 claims description 356
- 230000001605 fetal effect Effects 0.000 claims description 355
- 230000008774 maternal effect Effects 0.000 claims description 300
- 208000036878 aneuploidy Diseases 0.000 claims description 241
- 231100001075 aneuploidy Toxicity 0.000 claims description 191
- 239000000203 mixture Substances 0.000 claims description 155
- 210000002381 plasma Anatomy 0.000 claims description 90
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 74
- 230000003321 amplification Effects 0.000 claims description 73
- 230000003322 aneuploid effect Effects 0.000 claims description 50
- 230000002759 chromosomal effect Effects 0.000 claims description 47
- 210000004369 blood Anatomy 0.000 claims description 41
- 239000008280 blood Substances 0.000 claims description 41
- 238000003745 diagnosis Methods 0.000 claims description 29
- 238000009826 distribution Methods 0.000 claims description 28
- 208000026928 Turner syndrome Diseases 0.000 claims description 25
- 230000036961 partial effect Effects 0.000 claims description 25
- 238000007481 next generation sequencing Methods 0.000 claims description 24
- 238000000746 purification Methods 0.000 claims description 24
- 230000002441 reversible effect Effects 0.000 claims description 24
- 201000010374 Down Syndrome Diseases 0.000 claims description 22
- 208000037280 Trisomy Diseases 0.000 claims description 21
- 208000016679 Monosomy X Diseases 0.000 claims description 18
- 239000013060 biological fluid Substances 0.000 claims description 16
- 206010044688 Trisomy 21 Diseases 0.000 claims description 15
- 238000003786 synthesis reaction Methods 0.000 claims description 15
- 210000002966 serum Anatomy 0.000 claims description 14
- 201000009928 Patau syndrome Diseases 0.000 claims description 13
- 206010044686 Trisomy 13 Diseases 0.000 claims description 13
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 claims description 13
- 206010053884 trisomy 18 Diseases 0.000 claims description 13
- 201000006360 Edwards syndrome Diseases 0.000 claims description 11
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 210000002700 urine Anatomy 0.000 claims description 9
- 210000003296 saliva Anatomy 0.000 claims description 8
- 238000007841 sequencing by ligation Methods 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 206010062757 Trisomy 15 Diseases 0.000 claims description 4
- 206010053871 Trisomy 8 Diseases 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 206010044689 trisomy 22 Diseases 0.000 claims description 4
- 208000034298 trisomy chromosome 8 Diseases 0.000 claims description 4
- 239000000523 sample Substances 0.000 description 351
- 108020004414 DNA Proteins 0.000 description 148
- 238000012360 testing method Methods 0.000 description 120
- 108700028369 Alleles Proteins 0.000 description 90
- 108091092878 Microsatellite Proteins 0.000 description 75
- 239000000047 product Substances 0.000 description 65
- 239000012634 fragment Substances 0.000 description 58
- 239000002585 base Substances 0.000 description 49
- 239000002773 nucleotide Substances 0.000 description 49
- 238000003752 polymerase chain reaction Methods 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 47
- 206010028980 Neoplasm Diseases 0.000 description 46
- 125000003729 nucleotide group Chemical group 0.000 description 45
- 238000012217 deletion Methods 0.000 description 39
- 230000037430 deletion Effects 0.000 description 39
- 238000005516 engineering process Methods 0.000 description 39
- 108090000623 proteins and genes Proteins 0.000 description 35
- 102000040430 polynucleotide Human genes 0.000 description 33
- 108091033319 polynucleotide Proteins 0.000 description 33
- 239000002157 polynucleotide Substances 0.000 description 33
- 238000004458 analytical method Methods 0.000 description 31
- 239000011324 bead Substances 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 29
- 108091093088 Amplicon Proteins 0.000 description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 description 22
- 239000003153 chemical reaction reagent Substances 0.000 description 22
- 210000003754 fetus Anatomy 0.000 description 22
- 239000007790 solid phase Substances 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 19
- 230000008569 process Effects 0.000 description 19
- 230000002068 genetic effect Effects 0.000 description 17
- 239000012472 biological sample Substances 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 14
- 102000054765 polymorphisms of proteins Human genes 0.000 description 13
- 102000053602 DNA Human genes 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 208000031639 Chromosome Deletion Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000005259 peripheral blood Anatomy 0.000 description 11
- 239000011886 peripheral blood Substances 0.000 description 11
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 10
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 10
- 238000004364 calculation method Methods 0.000 description 10
- 239000000975 dye Substances 0.000 description 10
- 238000013467 fragmentation Methods 0.000 description 10
- 238000006062 fragmentation reaction Methods 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 238000001712 DNA sequencing Methods 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 230000005856 abnormality Effects 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 230000002255 enzymatic effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 8
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- -1 cfDNA Chemical class 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 230000035935 pregnancy Effects 0.000 description 8
- 230000005945 translocation Effects 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 206010036790 Productive cough Diseases 0.000 description 7
- 210000002593 Y chromosome Anatomy 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 102000054766 genetic haplotypes Human genes 0.000 description 7
- 238000003793 prenatal diagnosis Methods 0.000 description 7
- 210000003802 sputum Anatomy 0.000 description 7
- 208000024794 sputum Diseases 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 108010017826 DNA Polymerase I Proteins 0.000 description 6
- 102000004594 DNA Polymerase I Human genes 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000002559 cytogenic effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000004544 DNA amplification Effects 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 210000001766 X chromosome Anatomy 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000001351 cycling effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000003426 interchromosomal effect Effects 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 208000030454 monosomy Diseases 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000005382 thermal cycling Methods 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 206010061764 Chromosomal deletion Diseases 0.000 description 4
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 4
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 4
- 102000043276 Oncogene Human genes 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000007847 digital PCR Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000007672 fourth generation sequencing Methods 0.000 description 4
- 238000003205 genotyping method Methods 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 239000012521 purified sample Substances 0.000 description 4
- 238000007480 sanger sequencing Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 description 4
- 210000004243 sweat Anatomy 0.000 description 4
- 210000001138 tear Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 3
- 102100036254 E3 SUMO-protein ligase PIAS2 Human genes 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 3
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 201000000582 Retinoblastoma Diseases 0.000 description 3
- 108091035286 Strbase Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000002669 amniocentesis Methods 0.000 description 3
- 238000007846 asymmetric PCR Methods 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 238000005251 capillar electrophoresis Methods 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 210000004252 chorionic villi Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000004077 genetic alteration Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000007849 hot-start PCR Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 238000007403 mPCR Methods 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 208000014686 partial deletion of chromosome 11 Diseases 0.000 description 3
- 230000008775 paternal effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000012175 pyrosequencing Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000007862 touchdown PCR Methods 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 3
- 238000012176 true single molecule sequencing Methods 0.000 description 3
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 2
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- 241001136792 Alle Species 0.000 description 2
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 2
- 208000009575 Angelman syndrome Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108091061744 Cell-free fetal DNA Proteins 0.000 description 2
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 208000011359 Chromosome disease Diseases 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 238000006424 Flood reaction Methods 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000037699 Monosomy 18p Diseases 0.000 description 2
- 208000019209 Monosomy 22 Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 2
- 101150002130 Rb1 gene Proteins 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 108050002653 Retinoblastoma protein Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010071547 Trisomy 9 Diseases 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 230000007698 birth defect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 208000024971 chromosomal disease Diseases 0.000 description 2
- 208000004664 chromosome 18p deletion syndrome Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000011901 isothermal amplification Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 208000015994 miscarriage Diseases 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 230000005257 nucleotidylation Effects 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 125000001805 pentosyl group Chemical group 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000026817 47,XYY syndrome Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241001212612 Allora Species 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 102000003730 Alpha-catenin Human genes 0.000 description 1
- 108090000020 Alpha-catenin Proteins 0.000 description 1
- 102000007325 Amelogenin Human genes 0.000 description 1
- 108010007570 Amelogenin Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 108091011896 CSF1 Proteins 0.000 description 1
- 208000014392 Cat-eye syndrome Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000003449 Classical Lissencephalies and Subcortical Band Heterotopias Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101150114117 EGR1 gene Proteins 0.000 description 1
- 108010051748 Early Growth Response Protein 2 Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 230000010558 Gene Alterations Effects 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000691979 Halcyon Species 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- 208000030979 Language Development disease Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 201000004246 Miller-Dieker lissencephaly syndrome Diseases 0.000 description 1
- 208000035022 Miller-Dieker syndrome Diseases 0.000 description 1
- 208000010961 Monosomy 21 Diseases 0.000 description 1
- 208000033180 Monosomy 22q13.3 Diseases 0.000 description 1
- 208000010610 Mosaic trisomy 8 Diseases 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 208000003019 Neurofibromatosis 1 Diseases 0.000 description 1
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 1
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 1
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 1
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101000757182 Saccharomyces cerevisiae Glucoamylase S2 Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 201000001388 Smith-Magenis syndrome Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000004523 Sulfate Adenylyltransferase Human genes 0.000 description 1
- 108010022348 Sulfate adenylyltransferase Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 208000008963 Transient myeloproliferative syndrome Diseases 0.000 description 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 1
- 208000006812 Velopharyngeal Insufficiency Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010049644 Williams syndrome Diseases 0.000 description 1
- 208000006254 Wolf-Hirschhorn Syndrome Diseases 0.000 description 1
- 206010056894 XYY syndrome Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- IRLPACMLTUPBCL-FCIPNVEPSA-N adenosine-5'-phosphosulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO[P@](O)(=O)OS(O)(=O)=O)[C@H](O)[C@H]1O IRLPACMLTUPBCL-FCIPNVEPSA-N 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 108091092259 cell-free RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 108091092240 circulating cell-free DNA Proteins 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000013501 data transformation Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000011304 droplet digital PCR Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- LIYGYAHYXQDGEP-UHFFFAOYSA-N firefly oxyluciferin Natural products Oc1csc(n1)-c1nc2ccc(O)cc2s1 LIYGYAHYXQDGEP-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 238000003203 nucleic acid sequencing method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- JJVOROULKOMTKG-UHFFFAOYSA-N oxidized Photinus luciferin Chemical compound S1C2=CC(O)=CC=C2N=C1C1=NC(=O)CS1 JJVOROULKOMTKG-UHFFFAOYSA-N 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000009609 prenatal screening Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 102000004314 ribosomal protein S14 Human genes 0.000 description 1
- 108090000850 ribosomal protein S14 Proteins 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000008080 stochastic effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 208000015344 trisomy 17p Diseases 0.000 description 1
- 208000026485 trisomy X Diseases 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012418 validation experiment Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002569 water oil cream Substances 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B99/00—Subject matter not provided for in other groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6872—Methods for sequencing involving mass spectrometry
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2545/00—Reactions characterised by their quantitative nature
- C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
- C12Q2545/101—Reactions characterised by their quantitative nature the purpose being quantitative analysis with an internal standard/control
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Algebra (AREA)
- General Physics & Mathematics (AREA)
- Mathematical Analysis (AREA)
- Mathematical Optimization (AREA)
- Mathematical Physics (AREA)
- Pure & Applied Mathematics (AREA)
Claims (14)
1. Fremgangsmåde til fremstilling af et sekventeringsbibliotek fra en maternal prøve omfattende en blanding af føtale og materneile nukleinsyremolekyler, hvor fremgangsmåden omfatter på hinanden følgende trin af end-repairing, dA-addition og adaptor-ligering af disse nukleinsyrer, og hvor de på hinanden følgende trin udelukker oprensning af de end-repaired produkter før dA-additionstrinnet og udelukker oprensning af dA-additionsprodukterne før adaptor-ligeringstrinnet.
2. Fremgangsmåden ifølge krav 1, hvor de på hinanden følgende trin udføres i fraværet af polyethylenglycol.
3. Fremgangsmåden ifølge krav 1 eller krav 2, hvor de på hinanden følgende trin udføres i mindre end 1 time.
4. Anvendelse af sekventeringsbiblioteket fremstillet ved fremgangsmåden ifølge et hvilket som helst af kravene 1-3 i en massiv parallel fremgangsmåde til sekventering.
5. Anvendelsen ifølge krav 4, hvor fremgangsmåden til sekventering er en fremgangsmåde til bestemmelse af føtal kromosomal aneuploidi i den materneile prøve.
6. Anvendelsen ifølge krav 5, hvilken fremgangsmåde omfatter: (a) sekventering af mindst en del af nukleinsyremolekylerne i sekventeringsbiblioteket, hvorved opnås sekvensinformation for en mængdeaf føtale og materneile nukleinsyremolekyler fra en maternal prøve, hvor sekvensinformationen omfatter sekvenslæsninger; og (b) at anvende sekvensinformationen til at identificerede et antal kortlagte sekvensmærker for mindst ét normaliserende kromosom og for et aneuploidt kromosom, ved sammenligning af sekvenserne på sekvenslæsningerne med sekvensen fra et humant referencegenom for at bestemme den kromosomale oprindelse af de sekventerede nukleinsyremolekyler; (c) at beregne en kromosomdosis for det aneuploide kromosom som: (i) et forhold mellem antallet af kortlagte sekvensmærker identificeret for det aneuploide kromosom og antallet af kortlagte sekvensmærker identificeret for det mindst ene normaliserende kromosom; eller (ii) et forhold mellem et sekvensmærke-densitetsforhold for det aneuploide kromosom og et sekvensmærke-densitetsforhold for det mindst ene normaliserende kromosom, hvor sekvensmærke-densitetsforholdet for det aneuploide kromosom er beregnet ved at relatere antallet af kortlagte sekvensmærker identificeret for det aneuploide kromosom i trin (b) til længden af det aneuploide kromosom, og sekvensmærke-densitetsforholdet for det mindst ene normaliserende kromosom er beregnet ved at relatere antallet af kortlagte sekvensmærker identificeret for det mindst ene normaliserende kromosom i trin (b) med længden af det mindst ene normaliserende kromosom; og (d) at sammenligne denne dosis med en tærskelværdi, hvor tærskelværdien er et antal der tjener som en grænsediagnose for en aneuploidi, og derved bestemme tilstedeværelsen eller fraværet af føtal aneuploidi, hvor tilstedeværelsen af føtal aneuplodi er identificeret hvis den kromosomale dosis overstiger tærskelværdien, hvor: (i) det mindst ene normaliserende kromosom er et kromosom eller en gruppe af kromosomer der i et kvalificeret datasæt af prøver omfatter kromosomer der er til stede i et kendt kopiantal og ikke aneuploid for kromosomet af interesse viste en variabilitet i antallet af sekvensmærker kortlagt for det der bedst tilnærmet variabiliteten i antallet af sekvensmærker kortlagt til kromosomet af interesse; og/eller (ii) det mindst ene normaliserende kromosom er et kromosom eller en gruppe af kromosomer der tilvejebragte den største statistiske forskel mellem fordelingen af kromosomdoser for kromosomerne af interesse i et kvalificeret datasæt af prøver der omfatter kromosomer som er til stede i et kendt kopiantal og ikke aneuploid for kromosomerne af interesse og kromosomdosen for kromosomerne af interesse i én eller flere påvirkede prøver.
7. Anvendelsen ifølge krav 5 eller krav 6, hvor aneuploidien er en kromosomal aneuploidi.
8. Anvendelsen ifølge krav 5 eller krav 6, hvor aneuploidien er en delvis aneuploidi.
9. Anvendelsen ifølge krav 5 eller krav 6, hvor aneuploidien er en kromosomal aneuploidi valgt fra trisomi 8, trisomi 13, trisomi 15, trisomi 16, trisomi 18, trisomi 21, trisomi 22, monosomi X, XXX, XXY og XYY.
10. Anvendelsen ifølge krav 4, hvor fremgangsmåden til sekventering er en fremgangsmåde til at bestemme fraktionen af føtale nukleinsyrer i den materneile prøve.
11. Fremgangsmåden eller anvendelsen ifølge et hvilket som helst af de foregående krav, hvor den materneile prøve er en biologisk væske valgt fra blod, plasma, serum, urin og spyt.
12. Fremgangsmåden eller anvendelsen ifølge krav 11, hvor den materneile prøve er en plasmaprøve.
13. Fremgangsmåden eller anvendelsen ifølge et hvilket som helst af de foregående krav, hvor de føtale og materneile nukleinsyremolekyler er celle-fri DNA (cfDNA)-molekyler.
14. Anvendelsen ifølge krav 4, hvor sekventeringen: (i) er næste generations-sekventering (NGS); (ii) er massiv parallel sekventering under anvendelse af sekventering-ved-syntese med reversible farve-terminatorer; (iii) er massiv parallel sekventering under anvendelse af sekventering-ved-ligering; (iv) omfatter en amplifikation; eller (v) er enkelt-molekyle sekventering.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29635810P | 2010-01-19 | 2010-01-19 | |
US36083710P | 2010-07-01 | 2010-07-01 | |
US40701710P | 2010-10-26 | 2010-10-26 | |
US45584910P | 2010-10-26 | 2010-10-26 | |
PCT/US2010/058614 WO2011090559A1 (en) | 2010-01-19 | 2010-12-01 | Sequencing methods and compositions for prenatal diagnoses |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2366031T3 true DK2366031T3 (da) | 2015-02-23 |
Family
ID=44307118
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10830938.6T DK2366031T3 (da) | 2010-01-19 | 2010-12-01 | Fremgangsmåder til sekventering i prænatale diagnoser |
DK10830939.4T DK2376661T3 (da) | 2010-01-19 | 2010-12-01 | Simultan bestemmelse af aneuploidi og føtal fraktion |
DK18160303.6T DK3382037T3 (da) | 2010-01-19 | 2010-12-01 | Fremgangsmåder til bestemmelse af fraktionen af føtale nukleinsyrer i maternelle prøver |
DK10844163.5T DK2513339T3 (da) | 2010-01-19 | 2010-12-01 | Fremgangsmåde til bestemmelse af fraktion af føtal nukleinsyre i maternel-prøver |
DK17180803.3T DK3260555T3 (da) | 2010-01-19 | 2010-12-01 | Hidtil ukendt protokol til fremstilling af sekventeringsbiblioteker |
DK18201917.4T DK3492601T3 (da) | 2010-01-19 | 2010-12-01 | Hidtil ukendt protokol til fremstilling af sekvenseringsbiblioteker |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10830939.4T DK2376661T3 (da) | 2010-01-19 | 2010-12-01 | Simultan bestemmelse af aneuploidi og føtal fraktion |
DK18160303.6T DK3382037T3 (da) | 2010-01-19 | 2010-12-01 | Fremgangsmåder til bestemmelse af fraktionen af føtale nukleinsyrer i maternelle prøver |
DK10844163.5T DK2513339T3 (da) | 2010-01-19 | 2010-12-01 | Fremgangsmåde til bestemmelse af fraktion af føtal nukleinsyre i maternel-prøver |
DK17180803.3T DK3260555T3 (da) | 2010-01-19 | 2010-12-01 | Hidtil ukendt protokol til fremstilling af sekventeringsbiblioteker |
DK18201917.4T DK3492601T3 (da) | 2010-01-19 | 2010-12-01 | Hidtil ukendt protokol til fremstilling af sekvenseringsbiblioteker |
Country Status (12)
Country | Link |
---|---|
US (12) | US20110224087A1 (da) |
EP (14) | EP4450645A3 (da) |
AU (4) | AU2010343276B2 (da) |
CA (4) | CA2786357C (da) |
CY (1) | CY1124494T1 (da) |
DK (6) | DK2366031T3 (da) |
ES (6) | ES2560929T3 (da) |
GB (5) | GB2479080B (da) |
HK (6) | HK1160185A1 (da) |
PL (4) | PL2366031T3 (da) |
TR (1) | TR201807917T4 (da) |
WO (3) | WO2011090557A1 (da) |
Families Citing this family (241)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2313143T3 (es) | 2005-04-06 | 2009-03-01 | Maurice Stroun | Metodo para el diagnostico de cancer mediante la deteccion de adn y arn circulantes. |
US10081839B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc | System and method for cleaning noisy genetic data and determining chromosome copy number |
US10083273B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US8532930B2 (en) | 2005-11-26 | 2013-09-10 | Natera, Inc. | Method for determining the number of copies of a chromosome in the genome of a target individual using genetic data from genetically related individuals |
CA2647793C (en) * | 2006-02-28 | 2016-07-05 | University Of Louisville Research Foundation | Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms |
US20110033862A1 (en) * | 2008-02-19 | 2011-02-10 | Gene Security Network, Inc. | Methods for cell genotyping |
AU2009223671B2 (en) * | 2008-03-11 | 2014-11-27 | Sequenom, Inc. | Nucleic acid-based tests for prenatal gender determination |
US20110092763A1 (en) * | 2008-05-27 | 2011-04-21 | Gene Security Network, Inc. | Methods for Embryo Characterization and Comparison |
AU2009279734A1 (en) | 2008-08-04 | 2010-02-11 | Natera, Inc. | Methods for allele calling and ploidy calling |
US8962247B2 (en) | 2008-09-16 | 2015-02-24 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses |
US8476013B2 (en) | 2008-09-16 | 2013-07-02 | Sequenom, Inc. | Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
EP2473638B1 (en) | 2009-09-30 | 2017-08-09 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
CN107312844B (zh) | 2009-11-06 | 2021-01-22 | 香港中文大学 | 基于大小的基因组分析 |
US9315857B2 (en) | 2009-12-15 | 2016-04-19 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse label-tags |
US8835358B2 (en) | 2009-12-15 | 2014-09-16 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse labels |
EP3088532B1 (en) | 2009-12-22 | 2019-10-30 | Sequenom, Inc. | Processes and kits for identifying aneuploidy |
DK2366031T3 (da) * | 2010-01-19 | 2015-02-23 | Verinata Health Inc | Fremgangsmåder til sekventering i prænatale diagnoser |
EP2513341B1 (en) | 2010-01-19 | 2017-04-12 | Verinata Health, Inc | Identification of polymorphic sequences in mixtures of genomic dna by whole genome sequencing |
US10388403B2 (en) | 2010-01-19 | 2019-08-20 | Verinata Health, Inc. | Analyzing copy number variation in the detection of cancer |
US20120100548A1 (en) | 2010-10-26 | 2012-04-26 | Verinata Health, Inc. | Method for determining copy number variations |
US9323888B2 (en) | 2010-01-19 | 2016-04-26 | Verinata Health, Inc. | Detecting and classifying copy number variation |
WO2011091063A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Partition defined detection methods |
WO2011090556A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Methods for determining fraction of fetal nucleic acid in maternal samples |
US9260745B2 (en) | 2010-01-19 | 2016-02-16 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US20110312503A1 (en) | 2010-01-23 | 2011-12-22 | Artemis Health, Inc. | Methods of fetal abnormality detection |
US9090674B2 (en) * | 2010-05-17 | 2015-07-28 | The Board Of Regents Of The University Of Texas System | Rapid isolation of monoclonal antibodies from animals |
US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
WO2013052557A2 (en) * | 2011-10-03 | 2013-04-11 | Natera, Inc. | Methods for preimplantation genetic diagnosis by sequencing |
US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
CA2798758C (en) | 2010-05-18 | 2019-05-07 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US20130040375A1 (en) | 2011-08-08 | 2013-02-14 | Tandem Diagnotics, Inc. | Assay systems for genetic analysis |
US11203786B2 (en) | 2010-08-06 | 2021-12-21 | Ariosa Diagnostics, Inc. | Detection of target nucleic acids using hybridization |
US20130261003A1 (en) | 2010-08-06 | 2013-10-03 | Ariosa Diagnostics, In. | Ligation-based detection of genetic variants |
US11031095B2 (en) | 2010-08-06 | 2021-06-08 | Ariosa Diagnostics, Inc. | Assay systems for determination of fetal copy number variation |
US20140342940A1 (en) | 2011-01-25 | 2014-11-20 | Ariosa Diagnostics, Inc. | Detection of Target Nucleic Acids using Hybridization |
US10533223B2 (en) | 2010-08-06 | 2020-01-14 | Ariosa Diagnostics, Inc. | Detection of target nucleic acids using hybridization |
US10167508B2 (en) | 2010-08-06 | 2019-01-01 | Ariosa Diagnostics, Inc. | Detection of genetic abnormalities |
US8700338B2 (en) | 2011-01-25 | 2014-04-15 | Ariosa Diagnosis, Inc. | Risk calculation for evaluation of fetal aneuploidy |
US20120034603A1 (en) | 2010-08-06 | 2012-02-09 | Tandem Diagnostics, Inc. | Ligation-based detection of genetic variants |
ES2523140T3 (es) | 2010-09-21 | 2014-11-21 | Population Genetics Technologies Ltd. | Aumento de la confianza en las identificaciones de alelos con el recuento molecular |
MY169852A (en) * | 2010-11-30 | 2019-05-17 | Univ Hong Kong Chinese | Detection of genetic or molecular aberrations associated with cancer |
JP6328934B2 (ja) | 2010-12-22 | 2018-05-23 | ナテラ, インコーポレイテッド | 非侵襲性出生前親子鑑定法 |
US10131947B2 (en) | 2011-01-25 | 2018-11-20 | Ariosa Diagnostics, Inc. | Noninvasive detection of fetal aneuploidy in egg donor pregnancies |
US9994897B2 (en) | 2013-03-08 | 2018-06-12 | Ariosa Diagnostics, Inc. | Non-invasive fetal sex determination |
US11270781B2 (en) | 2011-01-25 | 2022-03-08 | Ariosa Diagnostics, Inc. | Statistical analysis for non-invasive sex chromosome aneuploidy determination |
US8756020B2 (en) | 2011-01-25 | 2014-06-17 | Ariosa Diagnostics, Inc. | Enhanced risk probabilities using biomolecule estimations |
EP2673729B1 (en) | 2011-02-09 | 2018-10-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US9260753B2 (en) | 2011-03-24 | 2016-02-16 | President And Fellows Of Harvard College | Single cell nucleic acid detection and analysis |
AU2012236200B2 (en) | 2011-03-30 | 2015-05-14 | Verinata Health, Inc. | Method for verifying bioassay samples |
PL3567124T3 (pl) | 2011-04-12 | 2022-04-19 | Verinata Health, Inc. | Rozdzielanie frakcji genomu z wykorzystaniem liczby polimorfizmu |
WO2012141712A1 (en) * | 2011-04-14 | 2012-10-18 | Verinata Health, Inc. | Normalizing chromosomes for the determination and verification of common and rare chromosomal aneuploidies |
GB2484764B (en) | 2011-04-14 | 2012-09-05 | Verinata Health Inc | Normalizing chromosomes for the determination and verification of common and rare chromosomal aneuploidies |
WO2014014498A1 (en) | 2012-07-20 | 2014-01-23 | Verinata Health, Inc. | Detecting and classifying copy number variation in a fetal genome |
US9411937B2 (en) * | 2011-04-15 | 2016-08-09 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US20130059738A1 (en) * | 2011-04-28 | 2013-03-07 | Life Technologies Corporation | Methods and compositions for multiplex pcr |
CN106912197B (zh) | 2011-04-28 | 2022-01-25 | 生命技术公司 | 用于多重pcr的方法和组合物 |
US20130059762A1 (en) | 2011-04-28 | 2013-03-07 | Life Technologies Corporation | Methods and compositions for multiplex pcr |
AU2012249531B2 (en) | 2011-04-29 | 2017-06-29 | Sequenom, Inc. | Quantification of a minority nucleic acid species |
WO2012177792A2 (en) | 2011-06-24 | 2012-12-27 | Sequenom, Inc. | Methods and processes for non-invasive assessment of a genetic variation |
EP2563937A1 (en) * | 2011-07-26 | 2013-03-06 | Verinata Health, Inc | Method for determining the presence or absence of different aneuploidies in a sample |
US8712697B2 (en) | 2011-09-07 | 2014-04-29 | Ariosa Diagnostics, Inc. | Determination of copy number variations using binomial probability calculations |
CA2848304A1 (en) * | 2011-09-09 | 2013-03-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for sequencing a polynucleotide |
US20130110407A1 (en) * | 2011-09-16 | 2013-05-02 | Complete Genomics, Inc. | Determining variants in genome of a heterogeneous sample |
US9984198B2 (en) | 2011-10-06 | 2018-05-29 | Sequenom, Inc. | Reducing sequence read count error in assessment of complex genetic variations |
US9367663B2 (en) | 2011-10-06 | 2016-06-14 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2013052913A2 (en) | 2011-10-06 | 2013-04-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US10196681B2 (en) | 2011-10-06 | 2019-02-05 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US20140242588A1 (en) | 2011-10-06 | 2014-08-28 | Sequenom, Inc | Methods and processes for non-invasive assessment of genetic variations |
US10424394B2 (en) | 2011-10-06 | 2019-09-24 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US8688388B2 (en) | 2011-10-11 | 2014-04-01 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
CA2851537C (en) | 2011-10-11 | 2020-12-29 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US9845552B2 (en) | 2011-10-27 | 2017-12-19 | Verinata Health, Inc. | Set membership testers for aligning nucleic acid samples |
JP6431769B2 (ja) | 2012-01-20 | 2018-11-28 | セクエノム, インコーポレイテッド | 実験条件を要因として含める診断プロセス |
ES2904816T3 (es) | 2012-02-27 | 2022-04-06 | Becton Dickinson Co | Composiciones para recuento molecular |
WO2013130512A2 (en) | 2012-02-27 | 2013-09-06 | The University Of North Carolina At Chapel Hill | Methods and uses for molecular tags |
WO2013128281A1 (en) | 2012-02-28 | 2013-09-06 | Population Genetics Technologies Ltd | Method for attaching a counter sequence to a nucleic acid sample |
EP3401399B1 (en) | 2012-03-02 | 2020-04-22 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US9892230B2 (en) | 2012-03-08 | 2018-02-13 | The Chinese University Of Hong Kong | Size-based analysis of fetal or tumor DNA fraction in plasma |
EP2831279B1 (en) | 2012-03-26 | 2023-05-03 | The Johns Hopkins University | Rapid aneuploidy detection |
CN103374518B (zh) * | 2012-04-12 | 2018-03-27 | 维里纳塔健康公司 | 拷贝数变异的检测和分类 |
DK2852680T3 (da) | 2012-05-21 | 2020-03-16 | Sequenom Inc | Fremgangsmåder og processer til ikke-invasiv evaluering af genetiske variationer |
US10504613B2 (en) | 2012-12-20 | 2019-12-10 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US9920361B2 (en) | 2012-05-21 | 2018-03-20 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
US10289800B2 (en) | 2012-05-21 | 2019-05-14 | Ariosa Diagnostics, Inc. | Processes for calculating phased fetal genomic sequences |
CN104053787A (zh) * | 2012-05-23 | 2014-09-17 | 深圳华大基因医学有限公司 | 鉴定双胞胎类型的方法和系统 |
US11261494B2 (en) * | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
US10497461B2 (en) | 2012-06-22 | 2019-12-03 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
AU2013290102B2 (en) | 2012-07-13 | 2018-11-15 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
EP2875156A4 (en) | 2012-07-19 | 2016-02-24 | Ariosa Diagnostics Inc | DETECTION BASED ON MULTIPLEX SEQUENTIAL LIGATION OF GENETIC VARIANTS |
US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
US11913065B2 (en) | 2012-09-04 | 2024-02-27 | Guardent Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
US10876152B2 (en) | 2012-09-04 | 2020-12-29 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
US20160040229A1 (en) | 2013-08-16 | 2016-02-11 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
WO2014039556A1 (en) | 2012-09-04 | 2014-03-13 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
US10482994B2 (en) | 2012-10-04 | 2019-11-19 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
CA2887094C (en) | 2012-10-04 | 2021-09-07 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
WO2014066635A1 (en) * | 2012-10-24 | 2014-05-01 | Complete Genomics, Inc. | Genome explorer system to process and present nucleotide variations in genome sequence data |
US10643738B2 (en) * | 2013-01-10 | 2020-05-05 | The Chinese University Of Hong Kong | Noninvasive prenatal molecular karyotyping from maternal plasma |
US20130309666A1 (en) | 2013-01-25 | 2013-11-21 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
KR102082025B1 (ko) | 2013-02-28 | 2020-02-26 | 더 차이니즈 유니버시티 오브 홍콩 | 대량 동시 rna 서열분석에 의한 모체 혈장 전사물 분석 |
EP2971100A1 (en) | 2013-03-13 | 2016-01-20 | Sequenom, Inc. | Primers for dna methylation analysis |
WO2014151511A2 (en) | 2013-03-15 | 2014-09-25 | Abbott Molecular Inc. | Systems and methods for detection of genomic copy number changes |
US20140278127A1 (en) * | 2013-03-15 | 2014-09-18 | Battelle Memorial Institute | Computer Files and Methods Supporting Forensic Analysis of Nucleotide Sequence Data |
EP2971097B1 (en) * | 2013-03-15 | 2018-08-01 | Verinata Health, Inc | Generating cell-free dna libraries directly from blood |
PL2981921T3 (pl) | 2013-04-03 | 2023-05-08 | Sequenom, Inc. | Metody i procesy nieinwazyjnej oceny zmienności genetycznych |
CN105555968B (zh) | 2013-05-24 | 2020-10-23 | 塞昆纳姆股份有限公司 | 遗传变异的非侵入性评估方法和过程 |
JP6521956B2 (ja) | 2013-06-17 | 2019-05-29 | ベリナタ ヘルス インコーポレイテッド | 性染色体におけるコピー数変異を判定するための方法 |
PL3011051T3 (pl) | 2013-06-21 | 2019-07-31 | Sequenom, Inc. | Sposób nieinwazyjnej oceny zmienności genetycznych |
ES2857908T3 (es) | 2013-08-28 | 2021-09-29 | Becton Dickinson Co | Análisis masivamente paralelo de células individuales |
GB201318369D0 (en) * | 2013-10-17 | 2013-12-04 | Univ Leuven Kath | Methods using BAF |
WO2015048535A1 (en) | 2013-09-27 | 2015-04-02 | Natera, Inc. | Prenatal diagnostic resting standards |
US10577655B2 (en) | 2013-09-27 | 2020-03-03 | Natera, Inc. | Cell free DNA diagnostic testing standards |
US10262755B2 (en) | 2014-04-21 | 2019-04-16 | Natera, Inc. | Detecting cancer mutations and aneuploidy in chromosomal segments |
EP3053071B1 (en) | 2013-10-04 | 2023-10-18 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
EP3055676A1 (en) | 2013-10-07 | 2016-08-17 | Cellular Research, Inc. | Methods and systems for digitally counting features on arrays |
EP3055427B1 (en) | 2013-10-07 | 2018-09-12 | Sequenom, Inc. | Methods and processes for non-invasive assessment of chromosome alterations |
EP3087204B1 (en) | 2013-12-28 | 2018-02-14 | Guardant Health, Inc. | Methods and systems for detecting genetic variants |
WO2015138774A1 (en) | 2014-03-13 | 2015-09-17 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
CA2945962C (en) | 2014-04-21 | 2023-08-29 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
EP3760739A1 (en) | 2014-07-30 | 2021-01-06 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
AU2015330734B2 (en) | 2014-10-10 | 2021-10-28 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
US9859394B2 (en) | 2014-12-18 | 2018-01-02 | Agilome, Inc. | Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids |
US10020300B2 (en) | 2014-12-18 | 2018-07-10 | Agilome, Inc. | Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids |
US10006910B2 (en) | 2014-12-18 | 2018-06-26 | Agilome, Inc. | Chemically-sensitive field effect transistors, systems, and methods for manufacturing and using the same |
US9857328B2 (en) | 2014-12-18 | 2018-01-02 | Agilome, Inc. | Chemically-sensitive field effect transistors, systems and methods for manufacturing and using the same |
US9618474B2 (en) | 2014-12-18 | 2017-04-11 | Edico Genome, Inc. | Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids |
EP3235010A4 (en) | 2014-12-18 | 2018-08-29 | Agilome, Inc. | Chemically-sensitive field effect transistor |
SG11201706529TA (en) | 2015-02-10 | 2017-09-28 | Univ Hong Kong Chinese | Detecting mutations for cancer screening and fetal analysis |
ES2824700T3 (es) | 2015-02-19 | 2021-05-13 | Becton Dickinson Co | Análisis unicelular de alto rendimiento que combina información proteómica y genómica |
KR101533792B1 (ko) * | 2015-02-24 | 2015-07-06 | 대한민국 | Ngs 기반 인간 객체의 상염색체 분석방법 |
WO2016138496A1 (en) | 2015-02-27 | 2016-09-01 | Cellular Research, Inc. | Spatially addressable molecular barcoding |
US11535882B2 (en) | 2015-03-30 | 2022-12-27 | Becton, Dickinson And Company | Methods and compositions for combinatorial barcoding |
EP3286326B1 (en) | 2015-04-23 | 2025-01-22 | Becton, Dickinson and Company | Method for whole transcriptome amplification |
US10844428B2 (en) * | 2015-04-28 | 2020-11-24 | Illumina, Inc. | Error suppression in sequenced DNA fragments using redundant reads with unique molecular indices (UMIS) |
EP3294906B1 (en) | 2015-05-11 | 2024-07-10 | Natera, Inc. | Methods for determining ploidy |
CA2986200A1 (en) | 2015-05-22 | 2016-12-01 | Nipd Genetics Public Company Limited | Multiplexed parallel analysis of targeted genomic regions for non-invasive prenatal testing |
US11124823B2 (en) | 2015-06-01 | 2021-09-21 | Becton, Dickinson And Company | Methods for RNA quantification |
EP3135770A1 (en) * | 2015-08-28 | 2017-03-01 | Latvian Biomedical Research and Study Centre | Set of oligonucleotides and method for detection of fetal dna fraction in maternal plasma |
US11302416B2 (en) | 2015-09-02 | 2022-04-12 | Guardant Health | Machine learning for somatic single nucleotide variant detection in cell-free tumor nucleic acid sequencing applications |
US10619186B2 (en) | 2015-09-11 | 2020-04-14 | Cellular Research, Inc. | Methods and compositions for library normalization |
US20180327844A1 (en) * | 2015-11-16 | 2018-11-15 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
EP3390668A4 (en) | 2015-12-17 | 2020-04-01 | Guardant Health, Inc. | METHODS OF DETERMINING THE NUMBER OF TUMOR GENE COPIES BY ACELLULAR DNA ANALYSIS |
US10982286B2 (en) | 2016-01-22 | 2021-04-20 | Mayo Foundation For Medical Education And Research | Algorithmic approach for determining the plasma genome abnormality PGA and the urine genome abnormality UGA scores based on cell free cfDNA copy number variations in plasma and urine |
JP7064665B2 (ja) | 2016-03-07 | 2022-05-11 | ファーザー フラナガンズ ボーイズ ホーム ドゥーイング ビジネス アズ ボーイズ タウン ナショナル リサーチ ホスピタル | 非侵襲的分子対照 |
CA3016360A1 (en) | 2016-04-15 | 2017-10-19 | Ucl Business Plc | Methods for lung cancer detection |
EP4269616A3 (en) | 2016-05-02 | 2024-02-14 | Becton, Dickinson and Company | Accurate molecular barcoding |
US10811539B2 (en) | 2016-05-16 | 2020-10-20 | Nanomedical Diagnostics, Inc. | Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids |
US10301677B2 (en) | 2016-05-25 | 2019-05-28 | Cellular Research, Inc. | Normalization of nucleic acid libraries |
WO2017205691A1 (en) | 2016-05-26 | 2017-11-30 | Cellular Research, Inc. | Molecular label counting adjustment methods |
EP3464626B1 (en) | 2016-05-27 | 2022-04-06 | Sequenom, Inc. | Methods for detecting genetic variations |
US10202641B2 (en) | 2016-05-31 | 2019-02-12 | Cellular Research, Inc. | Error correction in amplification of samples |
US10640763B2 (en) | 2016-05-31 | 2020-05-05 | Cellular Research, Inc. | Molecular indexing of internal sequences |
EP3491561A1 (en) | 2016-07-27 | 2019-06-05 | Sequenom, Inc. | Methods for non-invasive assessment of genomic instability |
CA3030890A1 (en) | 2016-07-27 | 2018-02-01 | Sequenom, Inc. | Genetic copy number alteration classifications |
AU2017328953B2 (en) * | 2016-09-15 | 2023-09-14 | Archerdx, Llc | Methods of nucleic acid sample preparation for analysis of cell-free DNA |
CA3037185A1 (en) | 2016-09-15 | 2018-03-22 | ArcherDX, Inc. | Methods of nucleic acid sample preparation |
KR102363716B1 (ko) | 2016-09-26 | 2022-02-18 | 셀룰러 리서치, 인크. | 바코딩된 올리고뉴클레오티드 서열을 갖는 시약을 이용한 단백질 발현의 측정 |
WO2018064486A1 (en) * | 2016-09-29 | 2018-04-05 | Counsyl, Inc. | Noninvasive prenatal screening using dynamic iterative depth optimization |
CN109642250B (zh) | 2016-09-30 | 2024-06-04 | 夸登特健康公司 | 用于无细胞核酸的多分辨率分析的方法 |
US9850523B1 (en) | 2016-09-30 | 2017-12-26 | Guardant Health, Inc. | Methods for multi-resolution analysis of cell-free nucleic acids |
WO2018067517A1 (en) | 2016-10-04 | 2018-04-12 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
WO2018085599A2 (en) * | 2016-11-02 | 2018-05-11 | ArcherDX, Inc. | Methods of nucleic acid sample preparation for immune repertoire sequencing |
SG11201903158RA (en) | 2016-11-08 | 2019-05-30 | Cellular Res Inc | Methods for cell label classification |
WO2018089378A1 (en) | 2016-11-08 | 2018-05-17 | Cellular Research, Inc. | Methods for expression profile classification |
US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
EP3568234B1 (en) | 2017-01-13 | 2023-09-06 | Cellular Research, Inc. | Hydrophilic coating of fluidic channels |
JP7051900B2 (ja) | 2017-01-18 | 2022-04-11 | イルミナ インコーポレイテッド | 不均一分子長を有するユニーク分子インデックスセットの生成およびエラー補正のための方法およびシステム |
EP3571614A1 (en) | 2017-01-20 | 2019-11-27 | Sequenom, Inc. | Methods for non-invasive assessment of copy number alterations |
CA3049682C (en) | 2017-01-20 | 2023-06-27 | Sequenom, Inc. | Methods for non-invasive assessment of genetic alterations |
CA3049455C (en) | 2017-01-20 | 2023-06-13 | Sequenom, Inc. | Sequencing adapter manufacture and use |
EP3574424A1 (en) | 2017-01-24 | 2019-12-04 | Sequenom, Inc. | Methods and processes for assessment of genetic variations |
MY197535A (en) | 2017-01-25 | 2023-06-21 | Univ Hong Kong Chinese | Diagnostic applications using nucleic acid fragments |
EP3577232A1 (en) | 2017-02-01 | 2019-12-11 | Cellular Research, Inc. | Selective amplification using blocking oligonucleotides |
WO2018156418A1 (en) | 2017-02-21 | 2018-08-30 | Natera, Inc. | Compositions, methods, and kits for isolating nucleic acids |
PT3596233T (pt) | 2017-03-17 | 2022-08-22 | Sequenom Inc | Métodos e processos para avaliação de mosaicismo genético |
JP7170711B2 (ja) * | 2017-04-18 | 2022-11-14 | アジレント・テクノロジーズ・ベルジャム・ナムローゼ・フェンノートシャップ | Dna分析のためのオフターゲット配列の使用 |
CA3059559A1 (en) | 2017-06-05 | 2018-12-13 | Becton, Dickinson And Company | Sample indexing for single cells |
EP3649258B1 (en) | 2017-07-07 | 2022-05-04 | Nipd Genetics Public Company Limited | Target-enriched multiplexed parallel analysis for assessment of fetal dna samples |
ES2924548T3 (es) | 2017-07-07 | 2022-10-07 | Nipd Genetics Public Company Ltd | Análisis paralelo multiplexado con enriquecimiento de blancos para la evaluación tumoral |
ES2925394T3 (es) | 2017-07-07 | 2022-10-17 | Nipd Genetics Public Company Ltd | Análisis paralelo multiplexado con enriquecimiento de blancos para la evaluación del riesgo de portar alteraciones genéticas |
PL3649257T3 (pl) | 2017-07-07 | 2022-07-18 | Nipd Genetics Public Company Limited | Wzbogacanie docelowych regionów genomowych do multipleksowej analizy równoległej |
LT3658689T (lt) | 2017-07-26 | 2021-06-25 | Trisomytest, S.R.O. | Neinvazinis prenatalinis vaisiaus chromosomos aneuploidijos nustatymo būdas iš motinos kraujo remiantis bajeso tinklu |
AU2018312117B2 (en) | 2017-08-04 | 2022-05-12 | Billiontoone, Inc. | Sequencing output determination and analysis with target-associated molecules in quantification associated with biological targets |
EP3662479A1 (en) | 2017-08-04 | 2020-06-10 | Trisomytest, s.r.o. | A method for non-invasive prenatal detection of fetal sex chromosomal abnormalities and fetal sex determination for singleton and twin pregnancies |
US11646100B2 (en) | 2017-08-04 | 2023-05-09 | Billiontoone, Inc. | Target-associated molecules for characterization associated with biological targets |
US11519024B2 (en) | 2017-08-04 | 2022-12-06 | Billiontoone, Inc. | Homologous genomic regions for characterization associated with biological targets |
US11447818B2 (en) | 2017-09-15 | 2022-09-20 | Illumina, Inc. | Universal short adapters with variable length non-random unique molecular identifiers |
CN108733982B (zh) * | 2017-09-26 | 2021-02-19 | 上海凡迪基因科技有限公司 | 孕妇nipt结果校正方法、装置及计算机可读存储介质、设备 |
WO2019084489A1 (en) | 2017-10-27 | 2019-05-02 | Juno Diagnostics, Inc. | DEVICES, SYSTEMS AND METHODS FOR ULTRA-LOW VOLUMES LIQUID BIOPSY |
JP2021506342A (ja) | 2017-12-14 | 2021-02-22 | ティーエーアイ ダイアグノスティックス インコーポレイテッドTai Diagnostics,Inc. | 移植のための移植片適合性の評価 |
CN111492068A (zh) | 2017-12-19 | 2020-08-04 | 贝克顿迪金森公司 | 与寡核苷酸相关联的颗粒 |
KR102031841B1 (ko) * | 2017-12-22 | 2019-10-15 | 테라젠지놈케어 주식회사 | 모체 시료 중 태아 분획을 결정하는 방법 |
DK3735470T3 (da) | 2018-01-05 | 2024-02-26 | Billiontoone Inc | Kvalitetskontroltemplates til sikring af validiteten af sekventeringsbaserede analyser |
WO2019195225A1 (en) | 2018-04-02 | 2019-10-10 | Illumina, Inc. | Compositions and methods for making controls for sequence-based genetic testing |
JP7573443B2 (ja) | 2018-04-14 | 2024-10-25 | ナテラ, インコーポレイテッド | 循環腫瘍dnaの個別化された検出を用いる癌検出およびモニタリングの方法 |
WO2019213237A1 (en) | 2018-05-03 | 2019-11-07 | Becton, Dickinson And Company | Molecular barcoding on opposite transcript ends |
AU2019262048A1 (en) | 2018-05-03 | 2020-11-12 | Becton, Dickinson And Company | High throughput multiomics sample analysis |
KR102447811B1 (ko) | 2018-05-17 | 2022-09-27 | 일루미나, 인코포레이티드 | 감소된 증폭 편향을 갖는 고속대량 단일 세포 서열분석 |
EP3833776A4 (en) | 2018-08-06 | 2022-04-27 | Billiontoone, Inc. | DILUTION MARKER FOR QUANTIFICATION OF BIOLOGICAL TARGETS |
JP2022511398A (ja) | 2018-10-01 | 2022-01-31 | ベクトン・ディキンソン・アンド・カンパニー | 5’転写物配列の決定 |
WO2020097315A1 (en) | 2018-11-08 | 2020-05-14 | Cellular Research, Inc. | Whole transcriptome analysis of single cells using random priming |
WO2020113577A1 (zh) * | 2018-12-07 | 2020-06-11 | 深圳华大生命科学研究院 | 一种靶基因文库的构建方法、检测装置及其应用 |
CN113195717A (zh) | 2018-12-13 | 2021-07-30 | 贝克顿迪金森公司 | 单细胞全转录组分析中的选择性延伸 |
WO2020150356A1 (en) | 2019-01-16 | 2020-07-23 | Becton, Dickinson And Company | Polymerase chain reaction normalization through primer titration |
EP4242322B1 (en) | 2019-01-23 | 2024-08-21 | Becton, Dickinson and Company | Oligonucleotides associated with antibodies |
AU2020216438A1 (en) | 2019-01-31 | 2021-07-29 | Guardant Health, Inc. | Compositions and methods for isolating cell-free DNA |
CN113454234A (zh) | 2019-02-14 | 2021-09-28 | 贝克顿迪金森公司 | 杂合体靶向和全转录物组扩增 |
US11965208B2 (en) | 2019-04-19 | 2024-04-23 | Becton, Dickinson And Company | Methods of associating phenotypical data and single cell sequencing data |
WO2020226528A1 (ru) * | 2019-05-08 | 2020-11-12 | Общество с ограниченной ответственностью "ГЕНОТЕК ИТ" | Способ определения кариотипа плода беременной женщины |
US11939622B2 (en) | 2019-07-22 | 2024-03-26 | Becton, Dickinson And Company | Single cell chromatin immunoprecipitation sequencing assay |
CN114269948B (zh) * | 2019-08-30 | 2025-01-28 | 香港中文大学 | 通过低深度基因组测序检测杂合性缺失的方法 |
WO2021087491A1 (en) | 2019-10-31 | 2021-05-06 | Sequenom, Inc. | Application of mosaicism ratio in multifetal gestations and personalized risk assessment |
CN114729350A (zh) | 2019-11-08 | 2022-07-08 | 贝克顿迪金森公司 | 使用随机引发获得用于免疫组库测序的全长v(d)j信息 |
CA3131748A1 (en) | 2019-11-22 | 2021-05-27 | Sarah E. SHULTZABERGER | Circulating rna signatures specific to preeclampsia |
WO2021146207A1 (en) | 2020-01-13 | 2021-07-22 | Becton, Dickinson And Company | Methods and compositions for quantitation of proteins and rna |
CN115335520A (zh) | 2020-01-29 | 2022-11-11 | 贝克顿迪金森公司 | 用于通过测序对单细胞进行空间映射的条形码化的孔 |
EP4111168A1 (en) | 2020-02-25 | 2023-01-04 | Becton Dickinson and Company | Bi-specific probes to enable the use of single-cell samples as single color compensation control |
CN115605614A (zh) | 2020-05-14 | 2023-01-13 | 贝克顿迪金森公司(Us) | 用于免疫组库谱分析的引物 |
CN111534604B (zh) * | 2020-05-27 | 2024-01-23 | 广东华美众源生物科技有限公司 | 一种检测人常染色体dip-str遗传标记的荧光复合扩增试剂盒 |
CN115803445A (zh) | 2020-06-02 | 2023-03-14 | 贝克顿迪金森公司 | 用于5撇基因表达测定的寡核苷酸和珠 |
US11932901B2 (en) | 2020-07-13 | 2024-03-19 | Becton, Dickinson And Company | Target enrichment using nucleic acid probes for scRNAseq |
US11377654B2 (en) | 2020-09-11 | 2022-07-05 | New England Biolabs, Inc. | Application of immobilized enzymes for nanopore library construction |
CN116635533A (zh) | 2020-11-20 | 2023-08-22 | 贝克顿迪金森公司 | 高表达的蛋白和低表达的蛋白的谱分析 |
AU2021391422A1 (en) | 2020-12-02 | 2022-11-03 | Illumina Software, Inc. | System and method for detection of genetic alterations |
AU2023240345A1 (en) | 2022-03-21 | 2024-10-10 | Billion Toone, Inc. | Molecule counting of methylated cell-free dna for treatment monitoring |
WO2024186778A1 (en) | 2023-03-03 | 2024-09-12 | Laboratory Corporation Of America Holdings | Methods and systems for positive cfdna screening on genetic variations using mosaicism ratio |
WO2024238593A1 (en) | 2023-05-15 | 2024-11-21 | Laboratory Corporation Of America Holdings | Machine-learning approaches to pan-cancer screening in whole genome sequencing |
CN117965744B (zh) * | 2023-12-12 | 2024-10-11 | 东莞博奥木华基因科技有限公司 | 一种基于多重pcr捕获技术检测胎儿样本倍性和母源细胞污染的试剂盒、引物和方法 |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6270961B1 (en) | 1987-04-01 | 2001-08-07 | Hyseq, Inc. | Methods and apparatus for DNA sequencing and DNA identification |
US5965362A (en) * | 1992-03-04 | 1999-10-12 | The Regents Of The University Of California | Comparative genomic hybridization (CGH) |
WO1994003638A1 (en) | 1992-07-30 | 1994-02-17 | Applied Biosystems, Inc. | Method of detecting aneuploidy by amplified short tandem repeats |
US5776737A (en) | 1994-12-22 | 1998-07-07 | Visible Genetics Inc. | Method and composition for internal identification of samples |
US6057103A (en) | 1995-07-18 | 2000-05-02 | Diversa Corporation | Screening for novel bioactivities |
AU735272B2 (en) | 1996-10-04 | 2001-07-05 | Intronn Llc | Sample collection devices and methods using markers and the use of such markers as controls in sample validation, laboratory evaluation and/or accreditation |
US20010051341A1 (en) | 1997-03-04 | 2001-12-13 | Isis Innovation Limited | Non-invasive prenatal diagnosis |
GB9704444D0 (en) | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
EP1591541B1 (en) | 1997-04-01 | 2012-02-15 | Illumina Cambridge Limited | Method of nucleic acid sequencing |
US5888740A (en) | 1997-09-19 | 1999-03-30 | Genaco Biomedical Products, Inc. | Detection of aneuploidy and gene deletion by PCR-based gene- dose co-amplification of chromosome specific sequences with synthetic sequences with synthetic internal controls |
AR021833A1 (es) | 1998-09-30 | 2002-08-07 | Applied Research Systems | Metodos de amplificacion y secuenciacion de acido nucleico |
US6440706B1 (en) * | 1999-08-02 | 2002-08-27 | Johns Hopkins University | Digital amplification |
EP1290225A4 (en) | 2000-05-20 | 2004-09-15 | Univ Michigan | METHOD FOR PRODUCING A DNA BANK BY POSITIONAL REPRODUCTION |
AU2001273057A1 (en) | 2000-06-27 | 2002-01-08 | Fluidigm Corporation | A microfluidic design automation method and system |
CA2413158A1 (en) | 2000-06-30 | 2002-01-10 | Incyte Genomics, Inc. | Ecm-related tumor marker |
US20020142324A1 (en) * | 2000-09-22 | 2002-10-03 | Xun Wang | Fungal target genes and methods to identify those genes |
WO2002060582A2 (en) | 2000-11-16 | 2002-08-08 | Fluidigm Corporation | Microfluidic devices for introducing and dispensing fluids from microfluidic systems |
US6691042B2 (en) | 2001-07-02 | 2004-02-10 | Rosetta Inpharmatics Llc | Methods for generating differential profiles by combining data obtained in separate measurements |
US7226732B2 (en) | 2001-07-16 | 2007-06-05 | Cepheid | Methods, apparatus, and computer programs for verifying the integrity of a probe |
US6927028B2 (en) | 2001-08-31 | 2005-08-09 | Chinese University Of Hong Kong | Non-invasive methods for detecting non-host DNA in a host using epigenetic differences between the host and non-host DNA |
US7893248B2 (en) | 2002-02-20 | 2011-02-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
KR20040102024A (ko) | 2002-03-01 | 2004-12-03 | 라브겐, 인코퍼레이티드 | 유전적 장애의 검출 방법 |
US6977162B2 (en) | 2002-03-01 | 2005-12-20 | Ravgen, Inc. | Rapid analysis of variations in a genome |
US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
US7727720B2 (en) | 2002-05-08 | 2010-06-01 | Ravgen, Inc. | Methods for detection of genetic disorders |
AU2003277153A1 (en) | 2002-09-27 | 2004-04-19 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
US10229244B2 (en) | 2002-11-11 | 2019-03-12 | Affymetrix, Inc. | Methods for identifying DNA copy number changes using hidden markov model based estimations |
ES2329364T3 (es) | 2003-01-17 | 2009-11-25 | The Trustees Of Boston University | Analisis de haplotipos. |
EP1583846B1 (en) | 2003-01-17 | 2011-11-16 | The Chinese University Of Hong Kong | Circulating mrna as diagnostic markers for pregnancy-related disorders |
JP4480715B2 (ja) | 2003-01-29 | 2010-06-16 | 454 コーポレーション | 二重末端シーケンシング |
EP1599608A4 (en) * | 2003-03-05 | 2007-07-18 | Genetic Technologies Ltd | Identification of fetal DNA and fetal cell marker in maternal plasma or serum |
EP1606417A2 (en) | 2003-03-07 | 2005-12-21 | Rubicon Genomics Inc. | In vitro dna immortalization and whole genome amplification using libraries generated from randomly fragmented dna |
EP1649040A4 (en) | 2003-07-10 | 2007-07-18 | Third Wave Tech Inc | ANALYSIS FOR DIRECT MEASUREMENT OF A GENE ASSAY |
WO2005023091A2 (en) | 2003-09-05 | 2005-03-17 | The Trustees Of Boston University | Method for non-invasive prenatal diagnosis |
WO2005039389A2 (en) | 2003-10-22 | 2005-05-06 | 454 Corporation | Sequence-based karyotyping |
US7252946B2 (en) | 2004-01-27 | 2007-08-07 | Zoragen, Inc. | Nucleic acid detection |
US20100216153A1 (en) | 2004-02-27 | 2010-08-26 | Helicos Biosciences Corporation | Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities |
US20100216151A1 (en) * | 2004-02-27 | 2010-08-26 | Helicos Biosciences Corporation | Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities |
US20060046258A1 (en) * | 2004-02-27 | 2006-03-02 | Lapidus Stanley N | Applications of single molecule sequencing |
EP1765503A2 (en) | 2004-03-03 | 2007-03-28 | The General Hospital Corporation | System for delivering a diluted solution |
US20090117542A1 (en) | 2004-05-17 | 2009-05-07 | The Ohio State University Research Foundation | Unique short tandem repeats and methods of their use |
DE102004036285A1 (de) | 2004-07-27 | 2006-02-16 | Advalytix Ag | Verfahren zum Bestimmen der Häufigkeit von Sequenzen einer Probe |
TW200624106A (en) | 2004-09-07 | 2006-07-16 | Uni Charm Corp | Warming article |
JP2007327743A (ja) | 2004-09-07 | 2007-12-20 | Univ Of Tokyo | 遺伝子コピーの解析方法及び装置 |
US20060178835A1 (en) | 2005-02-10 | 2006-08-10 | Applera Corporation | Normalization methods for genotyping analysis |
JP5219516B2 (ja) | 2005-03-18 | 2013-06-26 | ザ チャイニーズ ユニバーシティー オブ ホンコン | 染色体異数性の検出方法 |
WO2006131928A2 (en) | 2005-06-08 | 2006-12-14 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis |
US20060286558A1 (en) * | 2005-06-15 | 2006-12-21 | Natalia Novoradovskaya | Normalization of samples for amplification reactions |
DE102005057988A1 (de) | 2005-08-04 | 2007-02-08 | Bosch Rexroth Ag | Axialkolbenmaschine |
ES2739484T3 (es) | 2006-02-02 | 2020-01-31 | Univ Leland Stanford Junior | Prueba genética fetal no invasiva mediante análisis digital |
US20100184043A1 (en) | 2006-02-28 | 2010-07-22 | University Of Louisville Research Foundation | Detecting Genetic Abnormalities |
CA2647793C (en) * | 2006-02-28 | 2016-07-05 | University Of Louisville Research Foundation | Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms |
WO2007146105A2 (en) * | 2006-06-05 | 2007-12-21 | Cryo-Cell International, Inc. | Procurement, isolation and cryopreservation of fetal placental cells |
EP3425058A1 (en) | 2006-06-14 | 2019-01-09 | Verinata Health, Inc | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
EP2029779A4 (en) | 2006-06-14 | 2010-01-20 | Living Microsystems Inc | HIGHLY PARALLEL SNP GENOTYPING UTILIZATION FOR FETAL DIAGNOSIS |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
EP2589668A1 (en) * | 2006-06-14 | 2013-05-08 | Verinata Health, Inc | Rare cell analysis using sample splitting and DNA tags |
US20080050739A1 (en) * | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
EP2061801A4 (en) | 2006-06-14 | 2009-11-11 | Living Microsystems Inc | DIAGNOSIS OF FETAL ANOMALIES BY COMPARATIVE GENOMIC HYBRIDIZATION ANALYSIS |
EP3424598B1 (en) | 2006-06-14 | 2022-06-08 | Verinata Health, Inc. | Rare cell analysis using sample splitting and dna tags |
US20080113358A1 (en) | 2006-07-28 | 2008-05-15 | Ravi Kapur | Selection of cells using biomarkers |
WO2008015396A2 (en) | 2006-07-31 | 2008-02-07 | Solexa Limited | Method of library preparation avoiding the formation of adaptor dimers |
US8262900B2 (en) | 2006-12-14 | 2012-09-11 | Life Technologies Corporation | Methods and apparatus for measuring analytes using large scale FET arrays |
EP2118298B1 (en) | 2007-02-08 | 2013-01-09 | Sequenom, Inc. | Nucleic acid-based tests for rhd typing |
SI2183693T2 (sl) | 2007-07-23 | 2019-02-28 | The Chinese University Of Hong Kong Technology Licenising Office | Diagnosticiranje fetalne kromosomske anevploidije z uporabo genomskega sekvenciranja |
US12180549B2 (en) | 2007-07-23 | 2024-12-31 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using genomic sequencing |
CA2701726A1 (en) | 2007-10-04 | 2009-04-09 | Halcyon Molecular | Sequencing nucleic acid polymers with electron microscopy |
SG190670A1 (en) * | 2008-02-01 | 2013-06-28 | Gen Hospital Corp | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions |
AU2009223671B2 (en) * | 2008-03-11 | 2014-11-27 | Sequenom, Inc. | Nucleic acid-based tests for prenatal gender determination |
US20090299645A1 (en) | 2008-03-19 | 2009-12-03 | Brandon Colby | Genetic analysis |
WO2009120808A2 (en) * | 2008-03-26 | 2009-10-01 | Sequenom, Inc. | Restriction endonuclease enhanced polymorphic sequence detection |
US20090270601A1 (en) * | 2008-04-21 | 2009-10-29 | Steven Albert Benner | Differential detection of single nucleotide polymorphisms |
EP2853601B1 (en) | 2008-07-18 | 2016-09-21 | TrovaGene, Inc. | Methods for PCR-based detection of "ultra short" nucleic acid sequences |
LT2562268T (lt) * | 2008-09-20 | 2017-04-25 | The Board Of Trustees Of The Leland Stanford Junior University | Neinvazinis fetalinės aneuploidijos diagnozavimas sekvenavimu |
US20100285537A1 (en) | 2009-04-02 | 2010-11-11 | Fluidigm Corporation | Selective tagging of short nucleic acid fragments and selective protection of target sequences from degradation |
WO2011056094A2 (ru) * | 2009-10-26 | 2011-05-12 | Общество С Ограниченной Ответственностью "Апoгeй" | Пожарный вентиль |
CA2778926C (en) | 2009-10-26 | 2018-03-27 | Lifecodexx Ag | Means and methods for non-invasive diagnosis of chromosomal aneuploidy |
ES2934941T3 (es) * | 2009-11-05 | 2023-02-28 | Univ Hong Kong Chinese | Análisis genómico fetal a partir de una muestra biológica materna |
JP2013510580A (ja) | 2009-11-12 | 2013-03-28 | エソテリックス ジェネティック ラボラトリーズ, エルエルシー | 遺伝子座のコピー数の分析 |
WO2011091063A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Partition defined detection methods |
US9260745B2 (en) | 2010-01-19 | 2016-02-16 | Verinata Health, Inc. | Detecting and classifying copy number variation |
DK2366031T3 (da) | 2010-01-19 | 2015-02-23 | Verinata Health Inc | Fremgangsmåder til sekventering i prænatale diagnoser |
US9323888B2 (en) | 2010-01-19 | 2016-04-26 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US20120237928A1 (en) | 2010-10-26 | 2012-09-20 | Verinata Health, Inc. | Method for determining copy number variations |
US10388403B2 (en) | 2010-01-19 | 2019-08-20 | Verinata Health, Inc. | Analyzing copy number variation in the detection of cancer |
US20120100548A1 (en) | 2010-10-26 | 2012-04-26 | Verinata Health, Inc. | Method for determining copy number variations |
US20120270739A1 (en) | 2010-01-19 | 2012-10-25 | Verinata Health, Inc. | Method for sample analysis of aneuploidies in maternal samples |
EP2513341B1 (en) | 2010-01-19 | 2017-04-12 | Verinata Health, Inc | Identification of polymorphic sequences in mixtures of genomic dna by whole genome sequencing |
WO2011090556A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Methods for determining fraction of fetal nucleic acid in maternal samples |
US20110312503A1 (en) | 2010-01-23 | 2011-12-22 | Artemis Health, Inc. | Methods of fetal abnormality detection |
CA2825984A1 (en) | 2010-02-25 | 2011-09-01 | Advanced Liquid Logic, Inc. | Method of making nucleic acid libraries |
WO2012012037A1 (en) * | 2010-07-19 | 2012-01-26 | New England Biolabs, Inc. | Oligonucleotide adaptors: compositions and methods of use |
US20120034603A1 (en) | 2010-08-06 | 2012-02-09 | Tandem Diagnostics, Inc. | Ligation-based detection of genetic variants |
CN102409043B (zh) | 2010-09-21 | 2013-12-04 | 深圳华大基因科技服务有限公司 | 高通量低成本Fosmid文库构建的方法及其所使用标签和标签接头 |
MY169852A (en) | 2010-11-30 | 2019-05-17 | Univ Hong Kong Chinese | Detection of genetic or molecular aberrations associated with cancer |
US8877442B2 (en) | 2010-12-07 | 2014-11-04 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive determination of fetal inheritance of parental haplotypes at the genome-wide scale |
CN102127818A (zh) | 2010-12-15 | 2011-07-20 | 张康 | 利用孕妇外周血建立胎儿dna文库的方法 |
AU2011348267A1 (en) | 2010-12-23 | 2013-08-01 | Sequenom, Inc. | Fetal genetic variation detection |
WO2012103031A2 (en) | 2011-01-25 | 2012-08-02 | Ariosa Diagnostics, Inc. | Detection of genetic abnormalities |
EP2673729B1 (en) | 2011-02-09 | 2018-10-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
PL3567124T3 (pl) | 2011-04-12 | 2022-04-19 | Verinata Health, Inc. | Rozdzielanie frakcji genomu z wykorzystaniem liczby polimorfizmu |
GB2484764B (en) | 2011-04-14 | 2012-09-05 | Verinata Health Inc | Normalizing chromosomes for the determination and verification of common and rare chromosomal aneuploidies |
US9411937B2 (en) | 2011-04-15 | 2016-08-09 | Verinata Health, Inc. | Detecting and classifying copy number variation |
WO2014014498A1 (en) | 2012-07-20 | 2014-01-23 | Verinata Health, Inc. | Detecting and classifying copy number variation in a fetal genome |
EP2563937A1 (en) | 2011-07-26 | 2013-03-06 | Verinata Health, Inc | Method for determining the presence or absence of different aneuploidies in a sample |
-
2010
- 2010-12-01 DK DK10830938.6T patent/DK2366031T3/da active
- 2010-12-01 EP EP24186817.3A patent/EP4450645A3/en active Pending
- 2010-12-01 EP EP10825822.9A patent/EP2370599B1/en active Active
- 2010-12-01 WO PCT/US2010/058609 patent/WO2011090557A1/en active Application Filing
- 2010-12-01 PL PL10830938T patent/PL2366031T3/pl unknown
- 2010-12-01 US US12/958,356 patent/US20110224087A1/en not_active Abandoned
- 2010-12-01 EP EP21157398.5A patent/EP3878973B1/en active Active
- 2010-12-01 GB GB1108794.7A patent/GB2479080B/en active Active
- 2010-12-01 TR TR2018/07917T patent/TR201807917T4/tr unknown
- 2010-12-01 CA CA2786357A patent/CA2786357C/en active Active
- 2010-12-01 PL PL17180803T patent/PL3260555T3/pl unknown
- 2010-12-01 EP EP18160303.6A patent/EP3382037B1/en active Active
- 2010-12-01 US US12/958,353 patent/US9657342B2/en active Active
- 2010-12-01 AU AU2010343276A patent/AU2010343276B2/en active Active
- 2010-12-01 ES ES10844163.5T patent/ES2560929T3/es active Active
- 2010-12-01 PL PL10830939T patent/PL2376661T3/pl unknown
- 2010-12-01 AU AU2010343279A patent/AU2010343279B2/en active Active
- 2010-12-01 ES ES10830938.6T patent/ES2534758T3/es active Active
- 2010-12-01 GB GB1118396.9A patent/GB2485644B/en active Active
- 2010-12-01 GB GB1118398.5A patent/GB2485645B/en active Active
- 2010-12-01 ES ES10830939.4T patent/ES2534986T3/es active Active
- 2010-12-01 DK DK10830939.4T patent/DK2376661T3/da active
- 2010-12-01 CA CA2786544A patent/CA2786544C/en active Active
- 2010-12-01 EP EP17180803.3A patent/EP3260555B1/en not_active Revoked
- 2010-12-01 US US12/958,352 patent/US20110245085A1/en not_active Abandoned
- 2010-12-01 EP EP10830938.6A patent/EP2366031B1/en active Active
- 2010-12-01 DK DK18160303.6T patent/DK3382037T3/da active
- 2010-12-01 DK DK10844163.5T patent/DK2513339T3/da active
- 2010-12-01 EP EP21213836.6A patent/EP4074838A1/en active Pending
- 2010-12-01 EP EP14192156.9A patent/EP2883965B8/en active Active
- 2010-12-01 ES ES18160303T patent/ES2870533T3/es active Active
- 2010-12-01 AU AU2010343277A patent/AU2010343277B2/en active Active
- 2010-12-01 EP EP14192160.1A patent/EP2848703A1/en not_active Withdrawn
- 2010-12-01 EP EP10844163.5A patent/EP2513339B1/en active Active
- 2010-12-01 GB GB1107268.3A patent/GB2479471B/en active Active
- 2010-12-01 EP EP14192165.0A patent/EP2848704B1/en active Active
- 2010-12-01 ES ES18201917T patent/ES2909841T3/es active Active
- 2010-12-01 CA CA2785718A patent/CA2785718C/en active Active
- 2010-12-01 CA CA2786351A patent/CA2786351C/en active Active
- 2010-12-01 WO PCT/US2010/058614 patent/WO2011090559A1/en active Application Filing
- 2010-12-01 EP EP18201917.4A patent/EP3492601B1/en active Active
- 2010-12-01 DK DK17180803.3T patent/DK3260555T3/da active
- 2010-12-01 EP EP15181244.3A patent/EP3006573B1/en active Active
- 2010-12-01 GB GB1108795.4A patent/GB2479476B/en active Active
- 2010-12-01 DK DK18201917.4T patent/DK3492601T3/da active
- 2010-12-01 PL PL18201917T patent/PL3492601T3/pl unknown
- 2010-12-01 WO PCT/US2010/058612 patent/WO2011090558A1/en active Application Filing
- 2010-12-01 ES ES17180803T patent/ES2704701T3/es active Active
- 2010-12-01 AU AU2010343278A patent/AU2010343278B2/en active Active
- 2010-12-01 EP EP10830939.4A patent/EP2376661B1/en active Active
-
2011
- 2011-12-21 US US13/333,832 patent/US20120094849A1/en not_active Abandoned
-
2012
- 2012-01-18 HK HK12100602.6A patent/HK1160185A1/xx unknown
- 2012-01-19 HK HK12110851.3A patent/HK1170269A1/xx unknown
- 2012-01-19 HK HK12100648.2A patent/HK1160186A1/xx unknown
- 2012-01-19 HK HK12110871.9A patent/HK1170270A1/xx unknown
- 2012-02-02 US US13/365,240 patent/US20120165203A1/en not_active Abandoned
- 2012-03-19 HK HK12102728.1A patent/HK1162197A1/xx unknown
-
2013
- 2013-04-17 HK HK13104694.6A patent/HK1177232A1/zh unknown
-
2017
- 2017-05-22 US US15/601,951 patent/US10941442B2/en active Active
- 2017-07-31 US US15/664,008 patent/US11130995B2/en active Active
- 2017-07-31 US US15/664,043 patent/US11286520B2/en active Active
-
2021
- 2021-03-05 US US17/193,279 patent/US11884975B2/en active Active
- 2021-05-17 CY CY20211100424T patent/CY1124494T1/el unknown
- 2021-09-02 US US17/465,163 patent/US11952623B2/en active Active
- 2021-12-17 US US17/554,195 patent/US20220106639A1/en active Pending
-
2023
- 2023-12-11 US US18/534,929 patent/US20240150828A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11884975B2 (en) | Sequencing methods and compositions for prenatal diagnoses | |
US20220228197A1 (en) | Method for determining copy number variations | |
US20120270739A1 (en) | Method for sample analysis of aneuploidies in maternal samples | |
AU2022283736A1 (en) | Sequencing methods and compositions for prenatal diagnoses |